Charles River Laboratories International (CRL) Equity Average (2010 - 2025)

Charles River Laboratories International's Equity Average history runs 16 years deep, the most recent figure standing at $3.3 billion for Q4 2025.

• In Q4 2025, Equity Average fell 9.29% year-over-year to $3.3 billion; the TTM figure through Dec 2025 stood at $3.3 billion (down 9.29% YoY), while the FY2025 annual figure was $3.3 billion, down 6.12% from the prior year.
• Equity Average was $3.3 billion for Q4 2025 at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $3.8 billion in Q3 2024 to a low of $2.2 billion in Q1 2021.
• Historically, Equity Average has averaged $3.0 billion across 5 years, with a median of $3.2 billion in 2023.
• The sharpest annual moves came in 2021 and 2025: Equity Average surged 32.21% in 2021, then decreased 11.03% in 2025.
• A 5-year view of Equity Average shows it stood at $2.5 billion in 2021, then advanced by 12.93% to $2.8 billion in 2022, then increased by 23.14% to $3.5 billion in 2023, then rose by 4.85% to $3.6 billion in 2024, then decreased by 9.29% to $3.3 billion in 2025.
• The last three Equity Average figures came in at $3.3 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.3 billion (Q2 2025), per Business Quant data.